This MedLibrary.org supplementary page on Dobutamine is provided directly from the open source Wikipedia as a service to our readers. Please see the note below on authorship of this content, as well as the Wikipedia usage guidelines. To search for other content from our encyclopedia supplement, please use the form below:
Related Sponsors
 |
|
|
Dobutamine
|
|
| Systematic (IUPAC) name | |
| 4-[2-[3-(4-hydroxyphenyl)-1-methyl-propyl] aminoethyl]benzene-1,2-diol | |
| Identifiers | |
| CAS number | |
| ATC code | C01 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C18H23NO3 |
| Mol. mass | 301.38 g/mol |
| SMILES | & |
| Synonyms | Dobutrex Inotrex |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | 2 minutes |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Dobutamine is a sympathomimetic drug used in the treatment of heart failure and cardiogenic shock. Its primarcy mechanism is direct stimulation of β1 receptors of the sympathetic nervous system. It was developed by a laboratory led by Dr. Ronald Tuttle at Eli Lilly & Company.citation needed
Contents |
Use
Dobutamine is used to treat acute but potentially reversible heart failure, such as cardiac surgery or cases of septic or cardiogenic shock, on the basis of its positive inotropic action.[1]
Dobutamine can be used in cases of congestive heart failure to increase cardiac output. It is indicated when parenteral therapy is necessary for inotropic support in the short-term treatment of patients with cardiac decompensation due to depressed contractility, which could be the result of either organic heart disease or cardiac surgical procedures. It is not useful in ischemic heart disease because it increases heart rate and thus increases the heart's demand for oxygen.
Pharmacology
Dobutamine is a direct-acting agent whose primary activity results from stimulation of the β1-adrenoceptors of the heart, increasing contractility and cardiac output. Since it does not act on dopamine receptors to induce the release of norepinephrine (another α1 agonist), dobutamine is less prone to induce hypertension than is dopamine. Chronotropic, arrhythmogenic, and vasodilative effects are negligible.citation needed
Dobutamine is predominantly a β1-adrenergic agonist, with weak β2 activity, and α1 selective activity, although it is used clinically in cases of cardiogenic shock for its β1 inotropic effect in increasing heart contractility and cardiac output. Dobutamine is administered as a racemic mixture consisting of both (+) and (−) isomers, and the (+) isomer is a potent β1 agonist while the (−) isomer is a α1 agonist. Dobutamine also has mild β2 agonist activity.[2]
Side effects
Primary side effects include those commonly seen for β1 active sympathomimetics, such as hypertension, angina, arrhythmia, and tachycardia.[3]
References
- ^ Rang HP, Dale MM, Ritter JM, Flower RJ. Rang and Dale's Pharmacology.
- ^ Tibayan FA, Chesnutt AN, Folkesson HG, Eandi J, Matthay MA (1997). "Dobutamine increases alveolar liquid clearance in ventilated rats by beta-2 receptor stimulation". Am. J. Respir. Crit. Care Med. 156 (2 Pt 1): 438–44.
- ^ Shen, Howard (2008). Illustrated Pharmacology Memory Cards: PharMnemonics. Minireview, 6. ISBN 1-59541-101-1.
|
|||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||
Wikipedia content modification information:
- This page was last modified on 31 August 2008, at 19:45.
Wikipedia Authorship and Review
Wikipedia content provided here is not reviewed directly by MedLibrary.org. Wikipedia content is authored by an open community of volunteers and is not produced by or in any way affiliated with MedLibrary.org.
Wikipedia Usage Guidelines
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article on "Dobutamine".
The URL for this specific entry is:
All Wikipedia text is available under the terms of the GNU Free Documentation License. (See Copyrights for details). Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc.